

TSR-011 Clinical Development



LEERINK SWANN

- Target tumors with mutated ALK proteins and expression patterns
- IND submission in 2H12
- Phase 1 objectives:
 - MTD
 - Optimal dosing schedule
 - Target patient population
 - NSCLC with prior treatment with ALK inhibitors
 - NSCLC patients progressed while being treated with ALK inhibitors
 - Patients with other cancers who have ALK amplification, activating mutations, or other fusions